Navigation Links
Myoderm Adds Clinical Trial Supply Veteran to Business Development Team -- New UK Warehouse Operational and Increasing Drug Supply Volume
Date:8/8/2017

Myoderm, a global clinical trial drug supply specialist, today announced the addition of Andy Shepard to its business development team. This announcement comes on the heels of the opening of Myoderm’s European warehouse facility earlier this year. As the clinical trial market continues to expand globally, Myoderm has committed to adding staff and establishing operations to support its customers around the world.

Andy Shepard joins Myoderm as Associate Director, Business Development, Americas. In this role, he will manage the East Coast region for Myoderm. Most recently, Shepard was Regional Account Specialist for Fargo, ND-based Clinical Supplies Management (CSM), a global packaging and labeling company providing services to pharmaceutical and biotech companies. There for almost a decade, Shepard held positions of increasing responsibility in sales and business development.

“As clinical trials evolve, it’s critical that pharmaceutical and biotech companies have a supply partner that understands the complexities at hand and can navigate the changing landscape,” said Shepard. “Myoderm is known among its clients as that trusted partner who will get the job done and I am proud to be joining the team.”

Earlier this year, to meet the growing demand for global clinical trial drug supply, Myoderm opened a new clinical storage and distribution facility in Leicester, UK. This state-of-the-art, fully licensed warehouse is strategically located to provide greater access and faster delivery of clinical trial drugs, including biologics, to locations around the globe. This expanded global footprint has positioned Myoderm to offer more robust direct-to-site capabilities throughout Europe and Asia Pacific.

“Over the past 12-18 months, we’ve begun to see fundamental shifts in the clinical trial landscape that are heavily impacting the entire supply chain,” said Michael Cohen, CEO of Myoderm. “Supply managers and procurement teams are working hard to keep up with the impact of these changes. We are thrilled to add Andy’s expertise to the Myoderm team, expanding our ability to deliver innovative, customized drug sourcing and supply solutions.”

About Myoderm
Myoderm is a global clinical trial drug supply specialist, with more than 30 years of experience in sourcing, management and labeling of commercial drugs and supplies. Trusted by pharmaceutical companies, biotech companies, CROs and clinical trial packagers, Myoderm combines its deep expertise and obsession for customer service to deliver the most innovative, customized and efficient supply solutions. Myoderm is based outside of Philadelphia and maintains operations in Europe and Asia Pacific. For more information, visit http://www.myoderm.com.

Read the full story at http://www.prweb.com/releases/2017/08/prweb14579953.htm.


'/>"/>
Source: PRWeb
Copyright©2017 Vocus, Inc.
All rights reserved


Related biology technology :

1. The Journal of Allergy and Clinical Immunology Publishes Phase 2a Study Results With Cytos Biotechnologys CYT003 for the Treatment of Allergic Asthma
2. Positive Clinical Breast Cancer Data Presented for NuView’s Molecular Imaging Biomarker NLS-VPAC1
3. Neuralstem Announces 2012 Financial Results, Provides Clinical Trials Update
4. Ingenuity Systems and GeneInsight to Deliver an Interpretation and Reporting Workflow Solution to Clinical Laboratories
5. Greenwood Genetic Center Selects Cartagenia BENCHlab NGS, CNV Solutions for Clinical Data Analysis
6. Clinical Trials and Medical Research in Texas Create Jobs and Save Lives
7. Best Practices for Lean Six Sigma in Clinical Development and R&D, New Xtalks Life Sciences Webinar
8. Medical University of South Carolina Selects Elseviers Interdisciplinary Care Planning and Clinical Documentation Solution
9. Clinilabs Launches Research Volunteer Authentication Initiative Choosing Verified Clinical Trials to Stop Dual Enrollment in Clinical Trials
10. ISPE Releases New Guidance for Standardizing Use of Booklet Labels in Global Clinical Trials
11. Trigemina Receives ISP Approval of Clinical Study Protocol for TI-001 Phase 2 Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... and LAGUNA HILLS, Calif. , Oct. ... Cancer Research, London (ICR) and University ... SKY92, SkylineDx,s prognostic tool to risk-stratify patients with multiple myeloma ... MUK nine . The University of Leeds ... partly funded by Myeloma UK, and ICR will perform the ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, today confirmed licensing rights ... (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in collaboration with Children’s Hospital ...
(Date:10/10/2017)... ... October 10, 2017 , ... USDM Life Sciences , ... life sciences and healthcare industries, announces a presentation by Subbu Viswanathan and Jennifer ... “Automating GxP Validation for Agile Cloud Platforms,” will present a revolutionary approach to ...
(Date:10/9/2017)... ... 09, 2017 , ... The Giving Tree Wellness Center announces ... needs of consumers who are incorporating medical marijuana into their wellness and health ... As operators of two successful Valley dispensaries, The Giving Tree’s two founders, Lilach ...
Breaking Biology Technology:
(Date:4/13/2017)... -- According to a new market research report "Consumer IAM ... and Authorization), Service, Authentication Type, Deployment Mode, Vertical, and Region - Global ... grow from USD 14.30 Billion in 2017 to USD 31.75 Billion by ... ... MarketsandMarkets Logo ...
(Date:4/11/2017)... MELBOURNE, Florida , April 11, 2017 ... "Company"), a security technology company, announces the appointment of independent ... John Bendheim to its Board of Directors, furthering the ... ... behalf of NXT-ID, we look forward to their guidance and ...
(Date:4/5/2017)... LONDON , April 4, 2017 KEY ... is anticipated to expand at a CAGR of 25.76% ... neurodegenerative diseases is the primary factor for the growth ... full report: https://www.reportbuyer.com/product/4807905/ MARKET INSIGHTS The ... of product, technology, application, and geography. The stem cell ...
Breaking Biology News(10 mins):